BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  argenx to Provide Updates on Phase I/II Clinical Trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma During American Society of Hematology Annual Meeting

  The workshop will be held Monday, December 11th at 12:00 pm EST.

  December 11, 2017

   · 

  6 min read
• Drug Development

  Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

  These data from the company’s ongoing Phase 2 clinical trial in non-Hodgkin lymphoma (NHL) highlight exploratory response biomarkers and interim correlative data which may have the potential to further refine the clinical application of tazemetostat.

  December 11, 2017

   · 

  5 min read
• Business

  AuraBiosciences Strengthens Leadership Team with Addition of Cadmus Rich, M.D., as CMO

  In this role, Cadmus Rich, M.D. will oversee all clinical research and development activities.

  December 11, 2017

   · 

  4 min read
• Myriad Genetics Presents Results From Two Important EndoPredict Studies to the 2017 San Antonio Breast Cancer Symposium

  EndoPredict is a second-generation prognostic gene expression test for patients with breast cancer.

  December 11, 2017

   · 

  10 min read
• 

  FDA

  FDA Approves Sanofi’s Admelog, the First Follow-On Insulin to Control Sugar at Mealtime

  Admelog is a rapid-acting insulin similar to Humalog, another insulin lispro 100 Units/mL, currently approved in the U.S.

  December 11, 2017

   · 

  6 min read
• Drug Development

  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

  CRISPR gene-editing in hematopoietic stem cells demonstrates potential to treat β-thalassemia and sickle cell disease through upregulation of fetal hemoglobin.

  December 11, 2017

   · 

  5 min read
• Drug Development

  GBT Announces New Phase IIa Data at ASH for Voxelotor in Adolescents With Sickle Cell Disease (SCD)

  The HOPE-KIDS 1 Study is an ongoing open-label, single- and multiple-dose study evaluating the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor in a pediatric population with SCD.

  December 11, 2017

   · 

  8 min read
• Drug Development

  Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

  December 11, 2017

   · 

  10 min read
• Drug Development

  GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program

  The data were presented in oral and poster sessions during the 59th American Society of Hematology (ASH) Annual Meeting & Exposition at the Georgia World Congress Center in Atlanta.

  December 11, 2017

   · 

  12 min read
• Genmab’s 2017 R&D Update

  Genmab speakers will also discuss the company’s 2017 progress and key goals for 2018.

  December 11, 2017

   · 

  4 min read